Avanti Communications Share Discussion Threads

[extrader] 21/10/2012 17:45

Hi John,

I think there's a bit of a difference between RR (long-established FTSE 100 co, turnover of billions etc) lending £ 500m or so to long-standing, high tech suppliers and newco AVN allegedly lending/having to lend a proportionately much larger sum under opaque circumstances to a 2-bit telcom co ......

The other thing, of course, is that most FTSE co's are awash with cash...

General point noted , though.

ATB

[2350220] 21/10/2012 17:27

Interesting article in the Sunday Times today, about how big FTSE companies are 'Becoming their own banks' and lending to smaller companies who supply them.
I haven't got the paper, as I just happened to read the piece whilst in a coffee house. They mentioned Rolls Royce who have lent £500m !!! and folks are debating Avanti apparently lending £9m or thereabouts.

Anyone else read the article?

John

[jonnyno1] 21/10/2012 17:26

Dw sold 2.8million, slightly different to 28million, ooh by a factor of 10!

[idomeneo] 21/10/2012 15:17

EDIT Agreed that's what I meant to type, still huge compared to anything shareholders have got i.e. £0.00, or more accurately losses of £40m

DW sold£2.8million of shares some time ago so I think any DDs are inconsequential....

[djmozy2] 21/10/2012 12:00

The blog post is old - from 12th of October which conincided with the start of the bear raid to instill fear in everyone. From Tom Winfriths blog:
Avanti spokesmen insist that Filiago is growing and is profitable and moreover that no cash has gone out to it but this is merely the way that accountants treat Filiago switching its contracts to Hylas 1. I have to say that they do not make this clear.

[extrader] 21/10/2012 10:07

Hi Aishah,

Interesting article. The author (along with paulypilot) has called TNI well so far.....

Must say, if there were some basis to lorshipstrading's allegations re fancy accounting, a 'canny' management might want to make some other, lesser 'accounting changes' at short notice as an explanation for a post-statement price drop.....AVN management's failure to reply to awkward questions such as raised here is not helpful, esp given the havoc SC was able to wreak on the share price with other accounting-related allegations a while back.

You'd think they'd have learned their lesson !

I hold (both for self and other family members), so would like to get to the bottom of this.

GLA

[aishah] 19/10/2012 15:15

Avanti (AVN) ... still a space oddity. This guy is short AVN....

[lazyj] 19/10/2012 14:54

jojaken

Info available at squaremiledata.com
Oct 10th 3.05% - Oct 16th 4.56%
From Oct 11th the Closing S.P. has been holding/creeping up despite the additional short selling.
Intersting!

[jojaken] 19/10/2012 12:16

Thank you Nugacity. BTW where did you get these stats? TIA

[nugacity] 19/10/2012 11:56

Short position has increased from long term 3M or 3% to 5M or 5%

[yorgi] 19/10/2012 11:43

I know nothing about Lucian M but it was shown in early 2011 that the information that he was using to support his short was wrong (to say the least) but even when others admitted wrong information had been put out and apologised I don't recall SC having the strength of character to do the same.

I was reading his diary recently as he was posting about a small exploration company I have an interest in and on the two occasions he posted on neither could he even get the name right. However I'm sure he enjoyed his free dinner.

[sg31] 19/10/2012 11:42

If you put that lot on a balance. I can promise you that the side with Cawky on would be on the ground.

[jadeticl] 19/10/2012 11:36

So its Tom Bulford + Tom Winni versus Simon C + Lucian M. What a contest. Who in that lot is reliable, or indeed who is honest? Who has too much to lose if wrong? I think I would go for the Toms, on balance!

[2vdm] 19/10/2012 10:02

agreed, but for LTHs, a) his views shouldn't really worry us (particularly,for the sort of point you have highlighted in the baove post) and b)it provides a good opportunity to top up. I missed the 260s but still regard 270+ as a bargain. Just my view, but when my average used to be over £6, I thought that the long term prospects were there and overall, still think that they are.

[lavagrouch] 19/10/2012 09:21

Rathlindri post 11116 'jeez, things are bad when it gets to discussing football results on here'

Far rather this than the fear & panic on this board the last time SC announced he had gone short on Avanti. He & his associate's efforts at talking Avanti down this time do appear rather half-hearted - i wonder which of them will take it upon themselves to point out to the Singapore Government the error of their ways?

Grouch

[nugacity] 19/10/2012 08:25

Thank you for 11123 djmozy

[djmozy2] 19/10/2012 03:22

Copied from iii thread regarding TB:
Since the last Red Hot Penny Shares update I have spoken to David Williams, chief executive of AVANTI COMMUNICATIONS (AVN). He told me that the shortfall of c.£2m in the reported revenue, and the forecast that satellite capacity sales will occur later rather than sooner was primarily caused by the planned move from AIM to the Main List.

This could bring in some US investors who have more experience of valuing satellite operators. Avanti is keen to set the bar at a conservative level so as not to disappoint in the future.

He refuted my suggestion that sales into Europe might be made more difficult by the state of the economy, attributing any disappointment here to the efforts of his sales team. He also denied that pricing is under any pressure. Finally, he assured me that Avanti has plenty of cash on the balance sheet to carry it through to the point where the satellites are generating an operating cash flow.

In summary, the story has not really changed and Avanti is on track to be becoming a very profitable operator of three satellites. But Avanti must now deliver and, as I said last week, relatively small changes in the scale and timing of future profits and cash flow do have a disproportionate impact on the share price. But I am sticking to my guns, so BUY UP TO 750p (Current Price: 282p)

[jeffian] 18/10/2012 22:15

Did TB ask DW why he thought it was a good idea to put out an RNS stating that they were expecting to report revenues of £17.8m and then a few weeks later report revenues of £15m "in line with management expectations"? That seems to me to be the single issue that slaughtered the share price. It also taints any management guidance on sales going forward. Why should the market believe anything they say if they can simply produce a completely different figure without a by-your-leave? I doubt the market will take much notice of that "backlog" jargon now; they'll just wait to see if the cash comes into the bank.

[dunluce] 18/10/2012 20:38

Phsycho,

I must confess to being a tad reassured having read TB's comments after his chat with David Williams. I note that TB is prepared to sell/recommend selling stocks that he thinks have /will underperform and whilst I am under no illusion that DW will have glossed over a lacklustre set of results I hope that the share price reaction will have provided a salutary warning. On balance I remain positive re the outlook for AVN but any further disappointments.....

[phsycho] 18/10/2012 18:32

Well TB from RHPS states he he is happy with DWs explanations and AVN is still on track so no change to his recs.. for those who care what TB says.. :)

[rathlindri] 18/10/2012 16:09

Thanks Gary, fingers crossed there is some positive news that the market will like, we've taken a real hammering here since Hylas 2 launch early August....needless to say I bought in pre-launch at 432 in the hope of good things to come! It's hurting, quite a bit..

[garymott] 18/10/2012 15:39

rathlindri, an Interim Management Statement is due in November. See my post 11080.

[buywell2] 18/10/2012 15:34

Now for something completely different ...... good news

Note the 'deal' word here in the 2nd para and 2nd to last para

Cyprotex are a UK minnow with a Mkt Cap of circa $17m





GEN News Highlights : Oct 16, 2012

Sigma Divisions Establish Screening Technology DealsSigma Life Science's Sigma Advanced Genetic Engineering (SAGE) Labs, and Ekam Imaging are teaming up to develop a suite of preclinical services that will combine SAGE's rat models of neurological disorders and Ekam's functional magnetic resonance imaging (fMRI) technology.

Sigma Life Sciences separately announced a deal with ADME/tox services firm Cyprotex, through which the latter will be able to offer its clients knockout transporter screening services utilizing Sigma's CompoZr® zinc finger nuclease technology-based drug screening assays.

SAGE Labs' rat models have been engineered to reflect patient-relevant mutations and exhibit relevant phenotypes. Through the collaboration with Ekam the models will be studied using Ekam's fMRI technology, which can be used to provide detailed maps of a conscious animal's brain activity, unlike other fMRI studies that require anesthetized, unconscious animals, the firms claim. "Probing the brain functions of a conscious animals...produces data that is much more representative of a potential therapy's effect on human processes," comments Mark Nedelman, president and CEO at Ekam.

Sigma and Ekam plan to launch services based on SAGE Labs' neuroscience rat models in early 2013. Ekam is already using its technology to produce a detailed map of neural activity in SAGE Lab's Pink1 gene knockout rat, which has been generated for the Michael J. Fox Foundation to model Parkinson's disease, and exhibits delayed-onset motor deficits that mimic those of Parkinson's disease in humans.

The license agreement between Cyprotex and Sigma represents the first nonexclusive deal signed by the latter for the CompoZr-based knockout transporter cell assay technology. "These novel assays are key products of our highly predictive suite of engineered cell lines and transgenic animal models," remarks Paul Brooks, Ph.D., market segment manager for Sigma Life Sciences.

Cyprotex says the single and double functional knockout transporter services will allow it to offer clients specific, mechanistic assays to investigate the interaction of test compounds with MDR1 (P-gp), BCRP, and MRP2 transporters, without the use of chemical inhibitors that can interact with multiple transporters and produce an ambiguous representation of potential drug-drug interactions.





Sigma is a $8.9 BILLION Mkt Cap company

They have chosen Cyprotex as the first licencee of their new Transporter Technology which the FDA has recently been getting more UP on re testing requirements ..... says a lot methinks